EMA’s CHMP grants PRIME status to AbelZeta’s C-CAR168
C-CAR168 is aimed at depleting both autoreactive B cells and antibody-producing plasma cells.
Drug Development
Halozyme and Incyte sign licence agreement for INCA033989 formulations
Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal
Aptar unveils framework for injectable drug delivery systems
FDA grants traditional approval to Novartis’ Fabhalta for IgAN
JCVI issues recommendation on adolescent MenB vaccination in UK
Telix opens radiopharmaceutical facility in Australia for cancer treatment
Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy
